- Home
- MNPR vs KRNY Comparison
MNPR vs KRNY Comparison
Compare MNPR & KRNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- KRNY
- Stock Information
- Founded
- MNPR 2014
- KRNY 1884
- Country
- MNPR United States
- KRNY United States
- Employees
- MNPR N/A
- KRNY N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- KRNY Savings Institutions
- Sector
- MNPR Health Care
- KRNY Finance
- Exchange
- MNPR Nasdaq
- KRNY Nasdaq
- Market Cap
- MNPR 390.5M
- KRNY 420.7M
- IPO Year
- MNPR 2019
- KRNY 2005
- Fundamental
- Price
- MNPR $99.37
- KRNY $6.69
- Analyst Decision
- MNPR Strong Buy
- KRNY Buy
- Analyst Count
- MNPR 12
- KRNY 2
- Target Price
- MNPR $89.82
- KRNY $7.75
- AVG Volume (30 Days)
- MNPR 78.9K
- KRNY 421.7K
- Earning Date
- MNPR 11-07-2025
- KRNY 10-23-2025
- Dividend Yield
- MNPR N/A
- KRNY 6.61%
- EPS Growth
- MNPR N/A
- KRNY N/A
- EPS
- MNPR N/A
- KRNY 0.42
- Revenue
- MNPR N/A
- KRNY $151,629,000.00
- Revenue This Year
- MNPR N/A
- KRNY $14.22
- Revenue Next Year
- MNPR N/A
- KRNY N/A
- P/E Ratio
- MNPR N/A
- KRNY $15.95
- Revenue Growth
- MNPR N/A
- KRNY 12.84
- 52 Week Low
- MNPR $4.50
- KRNY $5.45
- 52 Week High
- MNPR $105.00
- KRNY $8.59
- Technical
- Relative Strength Index (RSI)
- MNPR 88.79
- KRNY 56.69
- Support Level
- MNPR $72.41
- KRNY $6.52
- Resistance Level
- MNPR $105.00
- KRNY $6.88
- Average True Range (ATR)
- MNPR 7.21
- KRNY 0.14
- MACD
- MNPR 2.86
- KRNY 0.01
- Stochastic Oscillator
- MNPR 89.52
- KRNY 55.42
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.